The FDA recently approved two new combination therapies for the treatment of HIV infection in adults. Both therapies are pharmacoenhanced protease inhibitors (PIs). Evotaz by Bristol-Myers Squibb is a combination of 300 mg atazanavir (Reyataz, Bristol-Myers Squibb) and 150 mg cobicistat (a pharmacokinetic enhancer by Gilead Sciences), which should be used with other antiretroviral agents. Evotaz should be dosed once a day. Read more bit.ly/1yga8lR
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.